Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 6/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.36 |
| ▸ | HPGDS | O60760 | 2/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.35 |
| ▸ | S100A9 | P06702 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31221920 | 1.00 | TDP1 (0.44) | TDP1HTTALDH1A1KDM4ELMNA | |
| SCHEMBL30681150 | 0.80 | ALDH1A1 (0.55) | TDP1HTTALDH1A1KDM4ELMNA | |
| SCHEMBL7216099 | 0.80 | ALDH1A1 (0.55) | TDP1HTTALDH1A1KDM4ELMNA | |
| SCHEMBL4964382 | 0.78 | HTT (0.60) | TDP1HTTALDH1A1KDM4ELMNA | |
| SCHEMBL1725892 | 0.78 | HTT (0.41) | TDP1HTTALDH1A1KDM4ELMNA | |
| SCHEMBL20270466 | 0.78 | HTT (0.55) | HTTALDH1A1KDM4ELMNAGAA | |
| SCHEMBL2530805 | 0.78 | S100A9 (0.46) | TDP1HTTALDH1A1KDM4ELMNA | |
| SCHEMBL22207146 | 0.78 | HTT (0.50) | TDP1HTTALDH1A1KDM4ELMNA | |
| SCHEMBL2896194 | 0.78 | HTT (0.41) | TDP1HTTALDH1A1KDM4ELMNA | |
| SCHEMBL7940220 | 0.78 | CHRNB2 (0.42) | HTTALDH1A1KDM4ELMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0556737-B1 | Process for the preparation of substituted 2,3-difluoro-pyridines | CLARIANT GMBH (DE) | 2000-01-12 | — | — | EP | claimed |
| US-5468863-A | Process for the preparation of substituted 2,3-difluoropyridines | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-11-21 | — | — | US | claimed |
| EP-0556737-A1 | Process for the preparation of substituted 2,3-difluoro-pyridines | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-08-25 | — | — | EP | claimed |
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-3898646-B1 | 3.ALPHA.-HYDROXY-17.BETA.-AMIDE NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | SAGE THERAPEUTICS LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4678641-A1 | QUINOLINONE COMPOUND AND NAPHTHYRIDINONE COMPOUND AND USE THEREOF | Shanghai Helioson Pharmaceutical Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| US-20250346572-A1 | NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF | LIEBER INST INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250197384-A1 | AZOLE COMPOUND AND ANTIFUNGAL AGENT | NIHON NOHYAKU CO., LTD. (JP) | 2025-06-19 | — | — | US | disclosed |
| EP-4539838-A1 | NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF | Lieber Institute, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| EP-4495114-A1 | AZOLE COMPOUND AND ANTIFUNGAL AGENT | Nihon Nohyaku Co., Ltd. (JP) | 2025-01-22 | — | — | EP | disclosed |
| WO-2024149378-A1 | QUINOLINONE COMPOUND AND NAPHTHYRIDINONE COMPOUND AND USE THEREOF | 上海超阳药业有限公司 | 2024-07-18 | — | — | WO | disclosed |
| EP-0700903-A1 | PROCESS FOR PRODUCING CYANOPYRIDINE | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 1996-03-13 | — | — | EP | disclosed |
| US-5468863-A | Process for the preparation of substituted 2,3-difluoropyridines | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-11-21 | — | — | US | disclosed |
| EP-0556737-A1 | Process for the preparation of substituted 2,3-difluoro-pyridines | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-08-25 | — | — | EP | disclosed |
| US-4853383-A | β-blocking substituted imidazoles | MERCK & CO., INC. (US) | 1989-08-01 | — | — | US | disclosed |
| US-4642311-A | β-adrenergic blocking imidazolylphenoxy propanolamines | MERCK & CO., INC. (US) | 1987-02-10 | — | — | US | disclosed |
| US-4567276-A | HYPOTENSIVE AGENTS, ADRENERGIC BLOCKING AGENTS | MERCK & CO., INC. (US) | 1986-01-28 | — | — | US | disclosed |
| US-4440774-A | ANTIHYPERTENSIVE AGENTS AND B-ANDRENERGIC BLOCKING AGENTS | MERCK & CO., INC. (US) | 1984-04-03 | — | — | US | disclosed |
| US-4199580-A | HYPOTENSIVE AGENTS AND ADRENERGIC BLOCKING AGENTS | MERCK & CO., INC. (US) | 1980-04-22 | — | — | US | disclosed |
| US-4134983-A | HYPOTENSIVE, ADRENERGIC BLOCKING AGENTS | MERCK & CO., INC. (US) | 1979-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346572-A1 | NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF | IP6K1, IP6K2, IP6K3 | TDP1 1411/4885HTT 2946/4885ALDH1A1 4134/4885 |
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | TDP1 1385/4885HTT 948/4885ALDH1A1 3835/4885 |
| US-20250197384-A1 | AZOLE COMPOUND AND ANTIFUNGAL AGENT | CBR3, ERG28, CBR1 | TDP1 4389/4885HTT 4206/4885ALDH1A1 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.